A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
Clinical trial NCT07748624 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07748624
- Sponsor
- Novartis Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-30
- Primary completion
- 2028-12-26
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.